ResearcherUniversity of BernActive in the last 2 years
Beat Gloor
Matched on ORCID iD 0000-0003-2135-605X; OpenAlex author ID A5030727384. Sources: OpenAlex.
Their work
- Papers
- 33 (first author 2, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 72
2011: 1 paper · 2012: 1 paper · 2013: 5 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 5 papers
Papers 33
- Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117188↗
- Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117453↗
- Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
- RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2026.101010↗
- ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18579-w↗
- Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heteroge… Co-author DOI 10.1038/s41416-025-02959-w↗
- Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies patient subgroups with adverse outcome. Co-author DOI 10.1186/s12885-025-14751-3↗
- Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18378-3↗
- Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Postoperative and Oncologic Outcomes Follow… Co-author DOI 10.3390/biomedicines13020333↗
- Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-0368↗
- Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal… Co-author DOI 10.1016/j.surg.2023.03.007↗
- Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Last author DOI 10.1136/gutjnl-2022-329371↗
- High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Co-author DOI 10.1016/j.ejca.2022.03.033↗
- PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups. Co-author DOI 10.1158/2326-6066.cir-21-0144↗
- Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.643529↗
- Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node … Co-author DOI 10.1007/s00423-020-01859-2↗
- Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000493466↗
- Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario. First author DOI 10.3390/cancers11070968↗
- Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Co-author DOI 10.1111/his.13508↗
- Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Co-author DOI 10.1158/1078-0432.ccr-17-3401↗
- 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
- PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. Co-author DOI 10.1016/j.ejca.2016.06.013↗
- Diagnostic Value and Interreader Agreement of the Pancreaticolienal Gap in Pancreatic Cancer on MDCT. Co-author DOI 10.1371/journal.pone.0166003↗
- Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal … Co-author DOI 10.1038/bjc.2015.177↗
- Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an inde… Co-author DOI 10.18632/oncotarget.2775↗
- The silencing of N-myc downstream-regulated gene-1 in an orthotopic pancreatic cancer model leads to more aggressive tumor growth and metastases. Co-author DOI 10.1159/000363065↗
- Trends in racial disparities in pancreatic cancer surgery. Co-author DOI 10.1007/s11605-013-2304-4↗
- Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2012.10.022↗
- Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment. First author DOI 10.1016/j.ejca.2013.03.028↗
- Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results r… Co-author DOI 10.1097/mpa.0b013e318291fbc5↗
- Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic du… Co-author DOI 10.1186/1479-5876-11-311↗
- How to counter the problem of R1 resection in duodenopancreatectomy for pancreatic cancer? Last author DOI 10.1007/s11605-011-1791-4↗
- N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Co-author DOI 10.1016/j.surg.2010.11.002↗
Closest collaborators
The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anna Silvia Wenning · 10 shared papers, 2022–2026 · strength 2.41
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenect… DOI 10.1245/s10434-025-18579-w↗
- Paper Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies p… DOI 10.1186/s12885-025-14751-3↗
- Eva Karamitopoulou · 16 shared papers, 2013–2026 · strength 2.25
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour… DOI 10.1038/s41416-025-02959-w↗
- Paper Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes… DOI 10.1158/1078-0432.ccr-24-0368↗
- Pauline Aeschbacher · 7 shared papers, 2023–2026 · strength 1.72
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenect… DOI 10.1245/s10434-025-18579-w↗
- Paper Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Ca… DOI 10.1245/s10434-025-18378-3↗
- Aurel A. Perren · 11 shared papers, 2013–2026 · strength 1.69
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour… DOI 10.1038/s41416-025-02959-w↗
- Paper Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes… DOI 10.1158/1078-0432.ccr-24-0368↗
- Martin Wartenberg · 10 shared papers, 2015–2026 · strength 1.57
- Paper Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour… DOI 10.1038/s41416-025-02959-w↗
- Paper Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies p… DOI 10.1186/s12885-025-14751-3↗
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117188↗
- Andréas Andreou · 6 shared papers, 2021–2026 · strength 1.32
- Paper ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenect… DOI 10.1245/s10434-025-18579-w↗
- Paper Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Ca… DOI 10.1245/s10434-025-18378-3↗
- Paper Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Pos… DOI 10.3390/biomedicines13020333↗
- Animesh Acharjee · 4 shared papers, 2021–2026 · strength 0.91
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes… DOI 10.1158/1078-0432.ccr-24-0368↗
- Paper Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancre… DOI 10.1136/gutjnl-2022-329371↗
- Konstantin Bräutigam · 3 shared papers, 2025–2026 · strength 0.82
- Paper RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged… DOI 10.1016/j.modpat.2026.101010↗
- Paper Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies p… DOI 10.1186/s12885-025-14751-3↗
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035↗
- Alessandro Lugli · 7 shared papers, 2013–2025 · strength 0.62
- Paper Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour… DOI 10.1038/s41416-025-02959-w↗
- Paper Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. DOI 10.1111/his.13508↗
- Paper Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotyp… DOI 10.1038/bjc.2015.177↗
- Romy Weber · 2 shared papers, 2025–2026 · strength 0.53
- Paper ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenect… DOI 10.1245/s10434-025-18579-w↗
- Paper Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Ca… DOI 10.1245/s10434-025-18378-3↗
- Martin D. Berger · 2 shared papers, 2025–2026 · strength 0.53
- Paper ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenect… DOI 10.1245/s10434-025-18579-w↗
- Paper Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Ca… DOI 10.1245/s10434-025-18378-3↗
- Maciej Garczyk · 2 shared papers, 2026 · strength 0.47
- Matteo Rossi Sebastiano · 2 shared papers, 2026 · strength 0.47
- Georgia Konstantinidou · 2 shared papers, 2026 · strength 0.47
- Shadi Katou · 2 shared papers, 2023–2025 · strength 0.42
- Paper Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Pos… DOI 10.3390/biomedicines13020333↗
- Paper Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy f… DOI 10.1016/j.surg.2023.03.007↗
- Benjamin Struecker · 2 shared papers, 2023–2025 · strength 0.42
- Paper Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Pos… DOI 10.3390/biomedicines13020333↗
- Paper Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy f… DOI 10.1016/j.surg.2023.03.007↗
- José A. Galván · 3 shared papers, 2015–2025 · strength 0.39
- Paper Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour… DOI 10.1038/s41416-025-02959-w↗
- Paper Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotyp… DOI 10.1038/bjc.2015.177↗
- Paper PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metas… DOI 10.1016/j.ejca.2016.06.013↗
- Mathias Worni · 5 shared papers, 2013–2020 · strength 0.35
- Paper Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreat… DOI 10.1007/s00423-020-01859-2↗
- Paper Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. DOI 10.1111/his.13508↗
- Paper Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Progno… DOI 10.1158/1078-0432.ccr-17-3401↗
- Michael Guenther · 1 shared paper, 2026 · strength 0.23
- Nic G. Reitsam · 1 shared paper, 2026 · strength 0.23
- Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
- Bruno Märkl · 1 shared paper, 2026 · strength 0.23
- Przemyslaw Grochowski · 1 shared paper, 2026 · strength 0.23
- Robert Grützmann · 1 shared paper, 2026 · strength 0.23
- Christian P. Pilarsky · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.